$7 Trillion For Chips and Drug Pricing | The Brainstorm EP 35
Feb 14, 2024
auto_awesome
Sam Korus, Nick Grous, Brett Winton, and Ali Urman discuss Sam Altman's plan to raise $7 trillion for an AI chip. They explore the exponential growth of AI, the impact of quantum, recreation, and AlphaGo, and the high drug prices in the US compared to other countries. They also analyze the viability of Mark Cuban's generics company and discuss the impact of drug pricing on affordability and access to care.
Sam Altman plans to raise $7 trillion for an AI chip, highlighting the need for massive investment to meet future hardware requirements for AI.
The Senate hearing on drug pricing exposes significant price differences for medications in the US compared to other countries, shedding light on the need for negotiation and affordability measures.
Deep dives
High AI Chip Spending: The Need for Future AI Hardware
The podcast discusses the news of Sam Altman's request for $5 trillion to build a giant chip-making facility for AI. The hosts explain the reasoning behind such a huge investment, stating that the scope is necessary to meet the future hardware requirements for AI. They break down the costs involved and the potential return on investment, highlighting the importance of building enough AI chips to power AI software and increase productivity in various industries. They also mention the need for automakers to invest more in EV capital. Overall, the discussion emphasizes the importance of capitalizing on disruptive technology to meet future demand.
Why Are Drug Prices Higher in the US?
The podcast delves into the Senate hearing that focused on the high cost of drugs in the US compared to other countries. The CEOs of Bristol-Myers Squibb, Merck, and Johnson & Johnson testified, highlighting the significant price differences for drugs like Eliquis in various countries. The discussion explores factors such as better access and multiple lines of therapy in the US, clinical trials conducted in the country, and the lack of negotiation for drug prices. It also touches on insurance's role in drug pricing and the challenges of finding a balance between recouping investment costs and ensuring affordability for patients. The podcast mentions Mark Cuban's generics company, Cost Plus Drugs, as a potential solution to provide cheaper options for medications once exclusivity is lost on patented drugs.
Challenges of Regulating Drug Prices in the US
The podcast highlights the challenges of regulating drug prices in the US, citing a lack of negotiations and relatively higher costs for medication. It mentions the ongoing efforts to negotiate Medicare pricing through the Inflation Reduction Act, which aims to lower drug costs. The podcast discusses the issue of patients failing to complete prescriptions due to cost and compares the failure rates between the US and other countries. It also touches on the toll-taking process and the need to find a balance between investors' return on investment and ensuring patients can afford necessary medications. The potential impact of Mark Cuban's generics company is mentioned as a viable business model in the generics market.
The Future of AI and its Impact on Humanity
The podcast touches on the future of AI and its implications for humanity. It references the book 'The Maniac' by Benjamin Labatt, which explores the potential consequences of AI development and the diminishing importance of humans in decision-making. The discussion highlights the concept of compounding progress in AI and the accelerating rate of technological advancements. The analogy of the chessboard is used to explain how the second half of the chessboard, representing the future, can lead to monumental gains and an abundance of possibilities. The podcast also addresses the fear of AI leading to human extinction and the need for open-source AI development. It emphasizes the importance of embracing the positive potential of AI while remaining mindful of its responsible and ethical use.
$7 trillion for an AI chip? This week, Autonomous Technology and Robotics Director of Research Sam Korus and Associate Portfolio Manager Nick Grous are joined by Chief Futurist Brett Winton and Multi-Omics Analyst Ali Urman. Together they discuss Sam Altman's plan to raise $7 trillion for an AI chip, and drug pricing.
If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn’t mean we don’t have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we’re sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Public.com. Tune in every week as we react to the latest in innovation. Here and there we’ll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK’s quick takes on what’s going on in tech today.
Key Points From This Episode:
$7 Trillion AI Chip
Fear and Regulation in AI
Drug Pricing
For more updates on Public.com:
Website: https://public.com/
YouTube: @publicinvest
Twitter: https://twitter.com/public
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode